Tamoxifen, one of the most well-known breast cancer drugs in modern oncology, has been gaining attention for its potential applications beyond breast cancer, including emerging research into brain tumors and neurodegenerative conditions that may interest those in the dementia and brain health community. Originally developed in the 1960s and approved for breast cancer treatment decades ago, tamoxifen belongs to a class of drugs called selective estrogen receptor modulators, and researchers have been investigating whether its ability to cross the blood-brain barrier could make it useful against glioblastomas and other central nervous system cancers. But tamoxifen is not the only breast cancer drug being repurposed. CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib — originally approved for hormone receptor-positive breast cancer — have shown promise in clinical trials for other cancer types, including certain lung cancers, brain metastases, and liposarcomas.
Abemaciclib in particular has drawn interest from neurological researchers because it penetrates the blood-brain barrier more readily than its counterparts. This article covers how these drugs work, which cancers they are being tested against, what the research means for brain health, and the significant limitations patients and caregivers should understand before drawing conclusions. This matters for our readership because cancer and dementia often coexist in aging populations, and treatment decisions for one condition can directly affect the other. Understanding drug repurposing — and its limits — is part of being an informed advocate.
Table of Contents
- Which Breast Cancer Drugs Are Being Tested Against Other Cancers?
- What Does the Research Say About Brain Penetration and Neurological Relevance?
- CDK4/6 Inhibitors Beyond Breast Cancer — Where the Trials Stand
- What Patients and Caregivers Should Know About Off-Label Drug Use
- Side Effects and Interactions Worth Watching in Older Adults
- The Broader Trend of Drug Repurposing in Oncology
- What to Expect Going Forward
- Conclusion
- Frequently Asked Questions
Which Breast Cancer Drugs Are Being Tested Against Other Cancers?
The primary drugs generating repurposing interest fall into two categories. The first is tamoxifen and related selective estrogen receptor modulators. Tamoxifen has been used for estrogen receptor-positive breast cancer since the 1970s and remains a frontline therapy. However, laboratory studies have shown that tamoxifen can inhibit protein kinase C and induce cell death in cancer types that do not rely on estrogen receptors at all, including certain gliomas. Some small clinical trials, mostly conducted in the 1990s and early 2000s, tested tamoxifen at high doses against recurrent glioblastoma with mixed but occasionally encouraging results.
The second category is the CDK4/6 inhibitors. Palbociclib was the first approved in this class, followed by ribociclib and abemaciclib. These drugs work by blocking cyclin-dependent kinases 4 and 6, proteins that help cancer cells divide. Because the CDK4/6 pathway is disrupted in many cancer types beyond breast cancer — including melanoma, non-small cell lung cancer, and certain sarcomas — researchers reasoned these drugs might have broader applications. As of recent reports, clinical trials have been exploring these drugs in at least a dozen non-breast cancer indications. However, having a biological rationale and having proven clinical benefit are two very different things, and most of these trials remain in early or intermediate phases.
What Does the Research Say About Brain Penetration and Neurological Relevance?
For those concerned with brain health, the critical question is whether these drugs can actually reach brain tissue in meaningful concentrations. Most chemotherapy drugs cannot effectively cross the blood-brain barrier, which is why brain cancers and brain metastases are notoriously difficult to treat. Tamoxifen does cross the blood-brain barrier, and cerebrospinal fluid concentrations have been documented in research settings. Abemaciclib also appears to achieve clinically relevant concentrations in the brain, which led to FDA breakthrough therapy designation for certain brain tumor indications in past years. However, if a patient or caregiver is reading this and thinking these drugs might help with dementia or cognitive decline directly, that is a significant leap the evidence does not currently support.
Some preclinical studies have explored whether tamoxifen has neuroprotective properties — its estrogen-modulating effects can influence neuroinflammation in animal models — but these laboratory findings have not translated into approved treatments or robust clinical trial data for Alzheimer’s disease or other dementias. The relevance to brain health is primarily indirect: these drugs may help treat brain cancers or brain metastases in patients who also happen to have cognitive concerns, and understanding their neurological side effects matters for dementia caregivers managing complex medication regimens. There is also a cautionary note. Tamoxifen at the high doses tested in brain cancer trials can cause side effects including blood clots, hot flashes, and in rare cases, cognitive changes. For older adults already experiencing cognitive decline, adding a drug with potential neurological side effects requires careful risk-benefit discussion with an oncologist and, ideally, a neurologist.
CDK4/6 Inhibitors Beyond Breast Cancer — Where the Trials Stand
Abemaciclib has been the most actively studied CDK4/6 inhibitor for non-breast cancers, in part because of its favorable brain penetration. Clinical trials have tested it against glioblastoma, with some early-phase results suggesting modest activity in specific molecular subtypes — particularly tumors with intact retinoblastoma protein expression and CDK4 or CDK6 amplification. A notable example is the study conducted through the Ivy Foundation Early Phase Clinical Trials Consortium, which evaluated abemaciclib in recurrent glioblastoma patients. Results were mixed overall, but a subset of patients with specific genetic markers showed more promising responses. Ribociclib and palbociclib have been tested in liposarcoma, a type of soft tissue cancer that frequently has CDK4 amplification.
Palbociclib received some attention after a phase 2 trial showed it could slow disease progression in well-differentiated and dedifferentiated liposarcomas. this is a genuinely useful example of drug repurposing, where a molecular target identified in one cancer type turns out to be relevant in another. The challenge is that response rates have generally been modest — these drugs tend to stabilize disease rather than shrink tumors dramatically — and insurers may not cover off-label use readily. For lung cancer, early trials have combined CDK4/6 inhibitors with existing therapies like immunotherapy or targeted agents. The idea is that blocking CDK4/6 might sensitize tumor cells to other treatments. These combination approaches are still being evaluated, and it would be premature to call them standard of care.
What Patients and Caregivers Should Know About Off-Label Drug Use
When a drug approved for breast cancer is used against a different cancer type, that is considered off-label prescribing. This is legal and common in oncology — some estimates suggest a substantial portion of cancer drugs are used off-label at some point. However, off-label use comes with practical tradeoffs that patients and caregivers need to understand. The first tradeoff is insurance coverage. Insurers may refuse to cover a drug used for an indication it was not approved for, even if an oncologist believes it is the best option. Some states have laws requiring coverage of off-label cancer drugs if they are supported by recognized medical compendia, but coverage battles remain common.
Patients may face out-of-pocket costs that can be substantial, particularly for CDK4/6 inhibitors, which have historically been among the more expensive oral cancer medications. The second tradeoff is evidence quality. An FDA-approved indication means the drug went through rigorous phase 3 trials for that specific cancer. Off-label use is often supported by earlier-phase data, case series, or biological plausibility rather than the gold standard of randomized controlled trials. This does not mean off-label use is wrong — sometimes it is the most reasonable option — but patients deserve transparency about how strong the evidence actually is. A caregiver managing medications for someone with both cancer and dementia should ask the oncologist directly: is this use supported by phase 3 data, or are we extrapolating from smaller studies?.
Side Effects and Interactions Worth Watching in Older Adults
One of the underappreciated concerns with repurposing breast cancer drugs in older adults — particularly those with cognitive impairment — is the side effect and interaction profile. Tamoxifen is metabolized through the CYP2D6 enzyme pathway, and many common medications can inhibit this enzyme, potentially reducing tamoxifen’s effectiveness or altering its side effect profile. Some antidepressants, including paroxetine and fluoxetine, are notable CYP2D6 inhibitors. Since depression is common in both cancer patients and dementia caregivers and patients, this interaction matters practically. CDK4/6 inhibitors carry their own concerns.
Neutropenia, or low white blood cell counts, is a frequent side effect and requires regular blood monitoring. For an older adult with dementia who may have difficulty communicating symptoms like fever or infection, this monitoring becomes even more critical. Fatigue is another common side effect that can be difficult to distinguish from dementia-related apathy or the general exhaustion of serious illness. A limitation worth stating plainly: most clinical trials of these drugs have enrolled relatively younger, healthier patients. Older adults with comorbidities like dementia are often excluded from trials, which means the safety and efficacy data may not fully apply to the populations most likely to face both cancer and cognitive decline simultaneously. Caregivers should advocate for geriatric oncology consultation when possible, as these specialists are trained to weigh the particular risks of cancer treatment in frail or cognitively impaired older adults.
The Broader Trend of Drug Repurposing in Oncology
Tamoxifen and CDK4/6 inhibitors are part of a much larger trend in cancer research. Drug repurposing — finding new uses for existing approved medications — has become an increasingly attractive strategy because it can shorten the timeline from laboratory to bedside. The safety profiles of approved drugs are already well characterized, which reduces some of the risk in early clinical testing.
Metformin, a diabetes drug, is another well-known example being studied across multiple cancer types and even in aging research more broadly. For the brain health community, the most relevant repurposing efforts to watch may not be breast cancer drugs at all, but rather cancer drugs being tested against neurodegeneration. Some researchers have explored whether certain kinase inhibitors developed for cancer could modulate the tau protein pathways implicated in Alzheimer’s disease. These efforts remain largely preclinical, but they illustrate how the boundaries between oncology and neurology are becoming less rigid as molecular medicine advances.
What to Expect Going Forward
The next several years will likely bring clearer answers about which breast cancer drugs genuinely earn a place in treating other cancers and which ones looked promising in early studies but failed to deliver in larger trials. Biomarker-driven approaches — where patients are selected for treatment based on the molecular profile of their tumor rather than just its location in the body — are reshaping how oncologists think about drug selection. This tumor-agnostic philosophy has already led to FDA approvals for some drugs across multiple cancer types based on shared genetic features rather than organ of origin.
For families navigating both cancer and dementia, staying informed about these developments matters, but so does maintaining realistic expectations. Drug repurposing is genuinely promising as a concept, yet the history of oncology is full of agents that showed early excitement and then disappointed in definitive trials. The best course of action remains working closely with medical teams who understand the full picture of a patient’s health, asking direct questions about evidence quality, and being cautious about claims that any single drug is a breakthrough across multiple diseases until the data clearly supports it.
Conclusion
Breast cancer drugs like tamoxifen and the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib are being actively investigated for use against other cancer types, including brain tumors, lung cancers, and sarcomas. The biological rationale is often sound — these drugs target molecular pathways that are disrupted across many cancers — and some early clinical results have been encouraging, particularly for abemaciclib’s ability to cross the blood-brain barrier. For the brain health community, these developments are worth following because cancer and cognitive decline frequently coexist in aging populations, and treatment choices for one condition inevitably affect the other.
That said, off-label drug use requires careful consideration of evidence quality, insurance coverage, side effects, and drug interactions, especially in older adults with dementia. Caregivers should ask oncologists specific questions about the strength of evidence behind any repurposed drug recommendation and seek geriatric oncology input when possible. The science of drug repurposing is advancing, but informed skepticism and good communication with medical teams remain the most reliable tools any patient or caregiver has.
Frequently Asked Questions
Is tamoxifen approved for any cancer other than breast cancer?
Tamoxifen has historically been FDA-approved primarily for breast cancer treatment and risk reduction. Any use for other cancer types, such as brain tumors, would be considered off-label. Patients should confirm current approval status with their oncologist, as regulatory decisions can change over time.
Can CDK4/6 inhibitors treat brain cancer?
Abemaciclib has been studied in clinical trials for glioblastoma and has shown ability to penetrate the blood-brain barrier. However, results have been mixed overall, with only certain molecular subtypes showing meaningful response. These drugs are not currently standard of care for brain cancers based on publicly available information as of recent reports.
Do these breast cancer drugs help with dementia or Alzheimer’s disease?
There is no clinical evidence supporting the use of tamoxifen or CDK4/6 inhibitors as treatments for dementia or Alzheimer’s disease. Some preclinical research has explored tamoxifen’s effects on neuroinflammation, but this has not translated into approved neurological therapies. Families should be cautious about extrapolating cancer research to dementia treatment.
What should a caregiver ask the oncologist about off-label cancer drug use?
Key questions include what level of evidence supports the recommendation, whether the drug has been tested specifically in older adults or patients with cognitive impairment, what monitoring will be needed, and whether insurance is likely to cover the off-label use. Requesting a geriatric oncology consultation is also reasonable.
Are there drug interactions between breast cancer drugs and dementia medications?
Tamoxifen is metabolized through CYP2D6, and some medications — including certain antidepressants commonly prescribed alongside dementia — can interfere with this pathway. CDK4/6 inhibitors are primarily metabolized through CYP3A4 and can interact with a range of common medications. A pharmacist review of all medications is advisable when adding any cancer drug to an existing regimen.
